Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held by Actinium Pharmaceuticals, Inc. on December 18, 2018. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Of the 114,698,044 shares eligible to vote, 90,895,072 shares (approximately 79.3%) were present in person or by proxy. All four proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): Sandesh Seth and Jeffrey W. Chell were elected as Class II directors for 36-month terms. Notably, Sandesh Seth received 22,304,222 votes "For" and 12,575,737 votes "Against," while Jeffrey W. Chell received 30,950,343 votes "For" and 3,733,590 votes "Against."
- Proposal 2 (Auditor Ratification): Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Proposal 3 (Stock Plan Amendment): An amendment to the 2013 Amended and Restated Stock Plan to increase authorized shares by 5 million was approved.
- Proposal 4 (Charter Amendment): An amendment to increase the authorized common stock to 600 million shares was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the significant "Against" vote count (12.5 million shares) for CEO Sandesh Seth's re-election compared to the other director nominee.
- Confirm the impact of the 5 million share increase to the stock plan on future dilution.
- Review the company's capital structure following the authorization increase to 600 million shares of common stock.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.